A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer

被引：0

作者：

Kaisa Leea Sunela

Sanna Koskinen

Pirkko-Liisa Kellokumpu-Lehtinen

机构：

[1] Tampere University Hospital,Department of Oncology

[2] University of Tampere Medical School,Department of Oncology

[3] University of Tampere,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2010年 / 66卷

关键词：

Renal cell carcinoma; Immunotherapy; Interferon; Pegylated; Chemotherapy; Capecitabine;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：59 / 67

页数：8

共 50 条

[21] A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer
Hong Suk Song
Young Rok Do
Heung Moon Chang
Min Hee Ryu
Kyung Hee Lee
Yeul Hong Kim
Dae Sik Hong
Jae Yong Cho
Kyoung Eun Lee
Si Young Kim
Cancer Chemotherapy and Pharmacology, 2008, 62 : 763 - 768
[22] A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer
Song, Hong Suk
Do, Young Rok
Chang, Heung Moon
Ryu, Min Hee
Lee, Kyung Hee
Kim, Yeul Hong
Hong, Dae Sik
Cho, Jae Yong
Lee, Kyoung Eun
Kim, Si Young
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (05) : 763 - 768
[23] RECOMBINANT INTERFERON ALFA-2A WITH OR WITHOUT VINBLASTINE IN METASTATIC RENAL-CELL CARCINOMA
FOSSA, SD
DEGARIS, ST
HEIER, MS
FLOKKMANN, A
LIEN, HH
SALVESON, A
MOE, B
CANCER, 1986, 57 (08) : 1700 - 1704
[24] Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer
Vahdat, Linda T.
Layman, Rachel
Yardley, Denise A.
Gradishar, William
Salkeni, Mohamad A.
Joy, Anil Abraham
Garcia, Agustin A.
Ward, Patrick
Khatcheressian, James
Sparano, Joseph
Rodriguez, Gladys
Tang, Shande
Gao, Ling
Dalal, Rita P.
Kauh, John
Miller, Kathy
ONCOLOGIST, 2017, 22 (03): : 245 - 254
[25] M-VAC COMBINATION IN LOCALLY ADVANCED, LOCALLY RECURRENT OR METASTATIC BREAST-CARCINOMA - A PHASE-II STUDY
BISAGNI, G
COCCONI, G
CECI, G
DELISI, V
DIBLASIO, B
LOTTICI, R
PASSALACQUA, R
FINARDI, C
ANNALS OF ONCOLOGY, 1994, 5 (01) : 93 - 94
[26] Characterisation of interferon alfa-2A and pegylated interferon alfa-2A in combination with ribavirin, mycophenolic acid or VX-497 as inhibitors of HCV replicon replication
Wilkinson, TCI
Laxton, C
Hobbs, E
Bartenschlager, R
Graves, M
Devos, R
Najera, I
JOURNAL OF HEPATOLOGY, 2001, 34 : 117 - 118
[27] Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma
Escudier, Bernard
Szczylik, Cezary
Hutson, Thomas E.
Demkow, Tomasz
Staehler, Michael
Rolland, Frederic
Negrier, Sylvie
Laferriere, Nicole
Scheuring, Urban J.
Cella, David
Shah, Sonalee
Bukowski, Ronald M.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) : 1280 - 1289
[28] A phase II study of lapatinib and capecitabine in second line treatment of locally advanced/metastatic pancreatic cancer
He, A. R.
Hwang, J. J.
Marshall, J.
Pishvaian, M.
Slack, R.
Weiner, L. M.
Wellstein, A.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[29] RECOMBINANT ALPHA INTERFERON IN METASTATIC RENAL-CELL CARCINOMA - A COOPERATIVE PHASE-II STUDY
BONO, AV
BRAUSI, M
REALI, L
VICINI, D
BENVENUTI, C
PAVONEMACALUSO, M
RIGATTI, P
ANSELMO, G
GIBBA, A
COPPI, F
COSCIANICUNICO, S
FRANCH, L
UROLOGY, 1991, 38 (01) : 60 - 63
[30] A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumbab for Locally Advanced or Metastatic Biliary Tract Cancer
Iyer, Renuka V.
Pokuri, Venkata K.
Groman, Adrienne
Ma, Wen W.
Malhotra, Usha
Iancu, Dan M.
Grande, Catherine
Saab, Tanios B.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (07): : 649 - 655

← 1 2 3 4 5 →